Letter to the Editor
Indeterminate cystic fibrosis newborn screening results
Clement L. Ren MD,
Corresponding Author
Clement L. Ren MD
Department of Pediatrics, University of Rochester, Rochester, New York
Correspondence to: C.L. Ren, MD, Department of Pediatrics, University of Rochester, Box 667/Room 4-3236, 601 Elmwood Avenue, Rochester, NY 14642. E-mail:
[email protected]Search for more papers by this author Richard Parad MD, MPH,
Richard Parad MD, MPH
Department of Pediatric Newborn Medicine, Brigham and Women's Hospital, Boston, Massachusetts
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
Search for more papers by this author Drucy Borowitz MD,
Drucy Borowitz MD
Department of Pediatric Pulmonology, State University of New York at Buffalo, Buffalo, New York
Search for more papers by this author
Clement L. Ren MD,
Corresponding Author
Clement L. Ren MD
Department of Pediatrics, University of Rochester, Rochester, New York
Correspondence to: C.L. Ren, MD, Department of Pediatrics, University of Rochester, Box 667/Room 4-3236, 601 Elmwood Avenue, Rochester, NY 14642. E-mail:
[email protected]Search for more papers by this author Richard Parad MD, MPH,
Richard Parad MD, MPH
Department of Pediatric Newborn Medicine, Brigham and Women's Hospital, Boston, Massachusetts
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
Search for more papers by this author Drucy Borowitz MD,
Drucy Borowitz MD
Department of Pediatric Pulmonology, State University of New York at Buffalo, Buffalo, New York
Search for more papers by this author
First published: 24 April 2014
No abstract is available for this article.
REFERENCES
- 1
Massie J,
Gillam L.
Uncertain diagnosis after newborn screening for cystic fibrosis: and ethics-based approach to a clinical dilemma.
Pediatr Pulmonol
2014;
49: 1–7.
- 2
Borowitz D,
Parad RB,
Sharp JK,
Sabadosa KA,
Robinson KA,
Rock MJ,
Farrell PM,
Sontag MK,
Rosenfeld M,
Davis SD, et al.
Cystic fibrosis foundation practice guidelines for the management of infants with cystic fibrosis transmembrane regulator-related metabolic syndrome during the first two years of life and beyond.
J Pediatr
2009;
155: S106–S116.
- 3
Fink A,
Elbert A,
Marshall B,
Wagener J.
Epidemiology and phenotypic variability of US patients with cystic fibrosis and the R117H mutation.
Pediatr Pulmonol
2013;
S36: 372.
- 4
Massie JR,
Wilcken B,
Van Asperen P,
Dorney S,
Gruca M,
Wiley V,
Gaskin K.
Pancreatic function and extended mutation analysis in delta F508 heterozygous infants with an elevated immunoreactive trysinogen but normal sweat chloride levels.
J Pediatr
2000;
137: 214–220.
- 5
Thauvin-Robinet C,
Munck A,
Huet F,
Génin E,
Bellis G,
Gautier E,
Audrézet M-P,
Férec C,
Lalau G,
Des Georges M, et al.
The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening.
J Med Genet
2009;
46: 752–758.
- 6
Parad R,
Comeau A,
Soultan Z,
Anbar R,
Pass K,
Caggana M,
Dorkin H,
Quizon A,
Waltz D,
Martin M, et al.
Outcomes of a cohort of immunoreactive trypsinogen (IRT)/DNA cystic fibrosis newborn screening (CFNBS) positive infants with R117H as one of two detected CFTR mutations: worrisome throat culture findings.
Pediatr Pulmonol
2005;
S28: 256.
- 7
Ren CL,
Desai H,
Platt M,
Dixon M.
Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome.
Pediatr Pulmonol
2011;
46: 1079–1184.
